Opinion
Video
Author(s):
The panel concludes with perspectives on the future of treatment for patients with colorectal cancer, including unmet needs in the disease space.
FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer
FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma
Isatuximab/VRd Elicits Sustained MRD Rates in Newly Diagnosed Myeloma
Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD
ALL Treatment Paradigm Displays Significant Gains as NCCN Guidelines Evolve
Revisit Every OncLive On Air Episode From November 2024
Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab
Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma
Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS